Literature DB >> 7217181

Multiple steroid hormone receptors in normal and abnormal human endometrium.

G Prodi, G Nicoletti, C De Giovanni, M C Galli, S Grilli, P Nanni, G Gola, R Rocchetta, C Orlandi.   

Abstract

The cytoplasmic concentrations of ER, AR, PR, and GR were determined in 124 specimens of normal and abnormal endometrium and other uterine human tissues by the DCC technique. In the endometrial carcinoma group, we observed that pretreatment with MAP leads to low cellularity, higher amount of AR, lower amounts of detectable ER, GR, and PR: the last receptor was almost always absent. A positive correlation between ER presence and tumor grade of differentiation was found in endometrial tumors from hormone-untreated patients. With the value of 142 fmol/mg DNA as the cut off point between high and low binding capacity, the frequency of the single receptors within the hormone-untreated cancer group ranged from 61% to 88%; ER and PR were simultaneously present in 55% of cases (they are tightly correlated in the different biopsies with respect to frequency and amount); ER-AR-PR were present in 45% and all the four receptors in 40% of cases. Slightly higher values were found in normal endometrium collected from hormone-untreated patients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7217181     DOI: 10.1007/bf00405961

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  29 in total

1.  Ultrafiltration studies of steroid-protein binding.

Authors:  P S CHEN; I H MILLS; F C BARTTER
Journal:  J Endocrinol       Date:  1961-10       Impact factor: 4.286

2.  Estrogen and progestogen binders in human and rat mammary carcinoma.

Authors:  L Terenius
Journal:  Eur J Cancer       Date:  1973-04       Impact factor: 9.162

3.  Estrogen receptor concentration in normal and pathological human uterine tissues.

Authors:  L H Evans; J D Martin; R Hähnel
Journal:  J Clin Endocrinol Metab       Date:  1974-01       Impact factor: 5.958

4.  Medroxyprogesterone in the management of primary and recurrent or metastatic uterine adenocarcinoma.

Authors:  J Bonte
Journal:  Acta Obstet Gynecol Scand Suppl       Date:  1972

5.  In vitro binding of progesterone by the human endometrium during the menstrual cycle and by hyperplastic, atrophic, and carcinomatous endometrium.

Authors:  M Haukkamaa; O Karjalainen; T Luukkainen
Journal:  Am J Obstet Gynecol       Date:  1971-09-15       Impact factor: 8.661

6.  Progesterone binding in human endometrial carcinomas.

Authors:  P C Young; C E Ehrlich; R E Cleary
Journal:  Am J Obstet Gynecol       Date:  1976-06-01       Impact factor: 8.661

7.  The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture.

Authors:  M Lippman; G Bolan; K Huff
Journal:  Cancer Res       Date:  1976-12       Impact factor: 12.701

8.  On receptors for estrogens (E2) and androgens (DHT) in human endometrial carcinoma and ovarian tumours.

Authors:  L G Friberg; S Kullander; J P Persijn; C B Korsten
Journal:  Acta Obstet Gynecol Scand       Date:  1978       Impact factor: 3.636

9.  Cytoplasmic receptors for 17 beta-estradiol, 5 alpha-dihydrotestosterone and progesterone in normal and abnormal human uterine tissues.

Authors:  S Grilli; A M Ferreri; G Gola; R Rocchetta; C Orlandi; G Prodi
Journal:  Cancer Lett       Date:  1977-03       Impact factor: 8.679

10.  [Effect of gestagen therapy upon estradiol- and progesterone-receptor-level and 17beta-hydroxysteroid dehydrogenase in human endometrial adenocarcinoma (author's transl)].

Authors:  K Pollow; E Boquoi
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1976-08-30
View more
  2 in total

1.  Premenopausal Circulating Androgens and Risk of Endometrial Cancer: results of a Prospective Study.

Authors:  Tess V Clendenen; Kathryn Hertzmark; Karen L Koenig; Eva Lundin; Sabina Rinaldi; Theron Johnson; Vittorio Krogh; Göran Hallmans; Annika Idahl; Annekatrin Lukanova; Anne Zeleniuch-Jacquotte
Journal:  Horm Cancer       Date:  2016-02-29       Impact factor: 3.869

Review 2.  Cancer in Jews: introduction and overview.

Authors:  Henry T Lynch; Wendy S Rubinstein; Gershon Y Locker
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.